carvykti
janssen-cilag international nv - ciltacabtagene autoleucel - multiple myeloma - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
blenrep
glaxosmithkline (ireland) limited - belantamab mafodotin - multiple myeloma - antineoplastische middelen - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
tecvayli
janssen-cilag international n.v. - teclistamab - multiple myeloma - antineoplastische middelen - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastische middelen - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
corsodyl mondspoeling, mondspoeling 2 mg/ml
top-pharma b.v. orionpoort 2 5971 lz grubbenvorst - chloorhexidinedigluconaat samenstelling overeenkomend met ; chloorhexidine - mondspoeling - ethanol 96 % ; macrogolglycerolhydroxystearaat ; pepermuntolie ; sorbitol (d-)(e 420) ; water, gezuiverd, - chlorhexidine
hibicet concentraat, concentraat voor oplossing voor cutaan gebruik 150 mg/ml en 15 mg/ml
mölnlycke health care ab gamlestadsvägen 3 c 415 02 gÖteborg (zweden) - cetrimide ; chloorhexidinedigluconaat - concentraat voor oplossing voor cutaan gebruik - benzylacetaat ; benzylbenzoaat ; citronellal ; diphenyloxide ; dipropyleenglycol ; ethanol ; geraniol ; gluconolacton (e 575) ; isoamylsalicylaat ; isobornylacetaat ; isopropylalcohol ; limoneen (d (+) vorm) ; methylsalicylaat ; natriumhydroxide (e 524) ; terpineol (ri) ; terpinoleen ; water, gezuiverd ; zonnegeel fcf (e 110), - chlorhexidine, combinations
hibiscrub, oplossing voor cutaan gebruik 40 mg/ml
dr. fisher farma b.v. - chloorhexidinedigluconaat - oplossing voor cutaan gebruik - citroenzuur aroma, kunstmatig ; gluconolacton (e 575) ; glycerol (e 422) ; isopropylalcohol ; lauryldimethylamine oxide ; macrogolglycerolcocoaat ; natriumhydroxide (e 524) ; poloxameer ; ponceau 4r (e 124) ; water, gezuiverd, - chlorhexidine
hibiscrub 40 mg/ml cut. opl.
mölnlycke health care ab se ab - chloorhexidinedigluconaat oplossing 0,2 ml - eq. chloorhexidinedigluconaat 40 mg - oplossing voor cutaan gebruik - 40 mg/ml - chloorhexidinedigluconaat 40 mg/ml - chlorhexidine
hibiscrub 40 mg/ml cut. opl. amp.
mölnlycke health care ab se ab - chloorhexidinedigluconaat oplossing 0,2 ml - eq. chloorhexidinedigluconaat 40 mg - oplossing voor cutaan gebruik - 40 mg/ml - chloorhexidinedigluconaat 40 mg/ml - chlorhexidine
biluron 150 mg, filmomhulde tabletten
genthon b.v. microweg 22 6545 cm nijmegen - bicalutamide 150 mg/stuk - filmomhulde tablet - crospovidon (e 1202) ; hypromellose (e 464) ; lactose 1-water ; macrogol 4000 ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat (e 487) ; povidon k 30 (e 1201) ; titaandioxide (e 171), - bicalutamide